BASF's Next Test: Turning Announced Projects Into Auditable Milestones
Published on 11/21/2026 at 12:41 | Editorial boerse-global.deBASF shareholders have two very different calendar entries to weigh against a stock that closed Wednesday's session down 2.6%: a capital markets day on 24 November, and a divestment whose completion is not expected until 2027. Neither offers a number investors can bank yet.
The agreed sale of the global mining solutions business to SNF, sealed on 12 November, gives the exit a firm contractual frame — but no financial terms were disclosed. Closing depends on regulatory clearances and customary conditions, so BASF has a buyer, not a completed divestiture. That distinction matters more for valuation than whether the share price bounces back after a weak Friday.
Execution, Not Agreement, Is the Hurdle
For the mining deal, the question is no longer whether the two sides can agree terms but whether they can carry them out. A smooth approval process would let BASF close on schedule, and the immediate gain would be presentational: investors could stop treating the unit as part of the future portfolio. No specific cash inflow or earnings benefit should be read into that.
Delay would be more awkward. If approvals slip or other conditions go unmet, the business stays inside BASF longer than planned, and anyone who has already priced in the exit would need to revisit the timeline. A falling share price is no reason to treat the sale as done. Nor would an on-time close prove the earnings picture has improved — until the financial conditions are published, the economic effect cannot be reliably assessed. Timely execution and a value-accretive sale are separate judgments.
Should investors sell immediately? Or is it worth buying BASF?
Evonik Exit Sets the Backdrop
The divestment follows BASF's decision on Thursday to end its takeover pursuit of Evonik after the specialty chemicals group rejected two unsolicited all-cash offers, the last at EUR 24 per Evonik share. BASF said a higher price would not be in its shareholders' interest. Jefferies, according to media reports, kept BASF at "Underperform" with a price target of 44 euros after the withdrawal — a stance that says nothing about individual projects but highlights the gap between a skeptical view of the equity and the potential management touts.
Soybean Trait Carries a Headline Number
Nemasphere, BASF's soybean technology, was announced for further development on 16 November. Varieties carrying the trait are slated for commercial launch in the US and Brazil from 2028, with the company putting peak sales potential at more than EUR 300 million. That figure describes an opportunity, not a forecast for the launch year and certainly not revenue already booked. What would sharpen the picture is detail on the conditions that must be met for commercialization in both countries and how the business might build after launch — the sort of staging that lets investors track progress without capitalizing the full peak number today.
Methanol Pact Needs a Project Pipeline
A cooperation with DWE on modular plants for sustainable methanol, agreed on Wednesday, sits at an earlier stage. It represents a business opportunity; it gains weight only if BASF can show how concrete projects will emerge from the collaboration. That would still not be secured revenue, but it would help investors gauge the commercial worth of the tie-up. Should the capital markets day stress potential without describing the route to capturing it, the methanol agreement remains a first step rather than a basis for assuming revenue.
What 24 November Must Deliver
The coming investor event is where these threads converge. If BASF holds to the 2028 launch window for Nemasphere and adds verifiable interim steps, the project could carry more weight in valuations. A slip in that timetable would push the first commercial sales further out, and the peak sales figure alone would not offset the lost time. Management's ability to translate announced ventures into auditable milestones is the measure that counts; absent that, the projects argue for possible additional revenue, not for a higher valuation multiple. Until the mining sale closes, the SNF agreement embodies an expectation about the future shape of the portfolio — not a quantifiable earnings forecast.
Ad
BASF Stock: New Analysis - 21 November
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
